Phase III Trial Shows 90.9% Proton Therapy Survival, Boosting LIXTE’s LiGHT Platform
Lancet Phase III trial shows five-year overall survival of 90.9% for oropharyngeal cancer patients treated with proton therapy versus 81% for photon radiation. LIXTE Biotechnology completed its acquisition of Liora Technologies Europe’s LiGHT proton therapy platform in November 2025 as U.S. centers, including Boca Raton’s summer facility, plan new investments.
1. Landmark Phase III Trial Results
The largest randomized Phase III trial to date enrolled 440 oropharyngeal cancer patients across 21 U.S. proton centers and found a five-year overall survival rate of 90.9% for proton therapy compared with 81% for traditional photon radiation, highlighting a significant clinical advantage in reducing collateral tissue exposure.
2. Expansion of U.S. Proton Therapy Infrastructure
Demand for proton therapy has prompted new investments in treatment centers nationwide, including a facility scheduled to open this summer in Boca Raton, Florida, as precision delivery and reduced exit dose drive infrastructure growth and attract capital from healthcare stakeholders.
3. LIXTE’s Strategic Acquisition of LiGHT Platform
In November 2025, LIXTE Biotechnology acquired European developer Liora Technologies, inheriting the electronically controlled LiGHT proton therapy platform to position the company at the forefront of the expanding proton therapy market and leverage emerging clinical data for commercial deployment.